Small Cap Feast

14th December 2023

Dish of the day
No Joiners today
Off the menu
No leavers today
 Small Cap Team will take a break until Monday 8 January 2024 after this Friday 15th December. Merry Christmas to all our readers.

Dish Of The Day:

Admissions: 
Investment Evolution Credit (AQSE: ICE): An U.K. registered fintech group that specialise in online consumer loans, announces its Admission to the AQSE Growth Market.

Delistings: 
OnTheMarket (OTMP.L) has left AIM.




Whats baking in the oven?

Potential Initial Public Offerings:

11 December: Kondor AI ITF: A U.K. registered AI company planning to launch the Kondor AI app, which will analyse pictures and live photos and provide solutions to questions and challenges based on visual input, is seeking Admission to the AQSE Growth Market. Expected AQSE Admission is on or around 21 December 2023.


30 November: Flex Labs ITF: a software business engaged in the development of advanced artificial intelligence (AI) middleware products, intending to offer these to business customers through a software as a service (SaaS) model announces its application for Admission to the AQSE Growth Market. Expected AQSE Admission date is on or around 15 December 2023.


2 October: Tekcapital announced intention to spin off and IPO: MicroSalt: the developer of salt-producing technology designed to deliver full flavor with less sodium, announces the launch of an exempt public offer of shares to retail investors for up to £2.5m via PrimaryBid as part of its spin out from AIM listed Tekcapital plc (TEK.L). Microsalt announced revenues of US$0.638m in 2022, its first year of retail sales of SaltMe Crisp brand and Microsalt salt shakers in US based supermarkets and through Amazon US. AIM Admission delayed, expected mid-December.


Reverse Takeovers:

06 December: Good Life Plus RTO: Formally Semper Fortis Esports Plc, announces its Admission to Access Segment of the Aquis Stock Exchange which constitutes a reverse take-over. Good Life Plus operates an entertainment focused monthly subscription service for consumers that provides access to daily luxury prize draws, along with numerous offers, discounts and rewards. Aquis Admission is expected 18 December.


30 November: EnergyPathways RTO: Formally Dial Square Investments Plc, listed on the Standard Listing of the Main Market, announces its Admission to AIM pursuant to the Acquisition of EnergyPathways Limited which constitutes a reverse take-over. EnergyPathways is an integrated energy transition company, initially targeting development of UK gas assets, with the aim of bringing these into production. AIM Admission is expected mid-December.


Change of Market:
05 December: AdvancedAdvT Limited (ADVT.L):
Intends to delist from its Standard Listing of the Main Market and apply for the Admission of its shares to trading on AIM on 10 January 2024.


Banquet Buffet

Celadon Pharmaceuticals 120p £64.6m (CEL.L)
The pharmaceutical company focused on the development, production and sale of cannabis-based medicines, announces the first supply of its pharmaceutical-grade product to the two commercial contracts announced on 24 May and 5 September 2023 respectively. Periodic invoicing has now commenced for both contracts, announced in May and September 2023, the first of which is worth a minimum of £3m of revenue, with up to £1.2m of revenue anticipated for the second contract. Since the announcement, the Company signed a further commercial contract with a European medicinal cannabis company and has the potential to generate revenue of up to £26m over three years, with the first delivery anticipated in H2 2024.

C4X Discovery Holdings 8.41p £21.2m (C4XD.L)
A Drug Discovery company, announces its full year audited results for the year ended 31 July 2023. Revenue of £1.7m (2022: £2.7m) and a total loss after tax of £11.1m (2022: £8.2m). The Company further announced net assets of £6.5m (2022: £11.8m) and holds net cash as at 31 July 2023: £4.2m (31 July 2022: £5.1m). C4XD announced that they signed an exclusive worldwide licensing agreement with AstraZeneca in November 2022, worth up to $402m, for its NRF2 Activator programme. Post-period, the Company received a payment of £15.95m from Indivior for the outright acquisition of Orexin-1 Receptor Antagonist Programme.

Driver Group 28p £14.6m (DRV.L)
The dispute avoidance and dispute resolution consultancy announces its preliminary results for the financial year ended 30 September 2023. Revenue decreased by 4% to £42.6m (2022: £45.1m) attributable to the restructured Middle East and Asia Pacific regions, however, gross profit margin was at 25% (2022: 21%), a £1.5m increase to £10.8m (2022: £9.3m). Underlying operating profit increase year on year of £1.4m to £1m (2022: Loss (£0.4m), and net cash increased year on year of £0.9m to £5.8m (2022: £4.9m). Utilisation improved to 72.5% (2022: 67.5%), and the Company announced post period Q1 revenue improving with an encouraging pipeline of new enquiries.

EnSilica 39p £30.5m (ENSI.L)
A chip maker of mixed signal ASICs (Application Specific Integrated Circuits), announces that it has conditionally raised approximately £1.56m by way of a placing at a price of 40 pence per new Ordinary Share. The Issue Price represents a discount of approximately 14 per cent to the closing mid-market price of an Ordinary Share on 13 December 2023. The net proceeds will be used to support the tender and execution of new and higher levels of activity, including: 1) seeking to secure two material ASIC design and supply contracts; 2) potential material contract for the "tape-out" and supply of a potentially high volume ASIC; and 3) progressing two consultancy contracts that may be worth, up to US$7.1m.

musicMagpie 13.75p £14.8m (MMAG.L)
A re-commerce business in the UK and US specialising in refurbished consumer technology, announces a pre-close trading update for the full year ended 30 November 2023. Full year revenue is expected to be £136.6m (2022: £143.3m), with a strong Black Friday period. Overall gross margin was 27.7% (2022: 26.2%), as a result, EBITDA is expected to be up 15.4% at £7.5m (2022: £6.5m). The number of active Rental subscribers grew by 21% in the year reaching 37,100 as at 30 November 2023 and net debt as at 30 November 2023 was £13.1m (31 May 2023: £13.6m). The Board is encouraged by musicMagpie's H2 performance and remains confident in its medium-term prospects.

Pantheon Resources 19.12p £175.7m (PANR.L)
The oil and gas company with a 100% working interest in the Kodiak and Ahpun projects, share the complete results of its multiyear leasing programme. Pantheon has been awarded 66,240 acres on the North Slope covering all of the anticipated remaining conventional reservoir potential in the Kodiak Field and the potential eastern extent of the Ahpun Field covered by the 23,040 acres that could be accessed from the West side of the Sag River using current technologies. Pantheon's winning bids averaged $31.83 per acre including fees. When the leases are officially awarded by the State of Alaska, estimated to be in 4 to 6 months' time and they will come with a 10-year initial term.

Sareum Holdings* 57.5p £40.4m (SAR.L)
A biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, publishes an update on operational activities and pipeline progress ahead of its Annual General Meeting (AGM) taking place today at 10.00 am at 85 Gresham Street, London EC2V 7NQ. The Company made good progress in 2023 with its lead programme, SDC-1801, with a Phase 1a clinical trial underway in Australia. Full safety data from the Phase 1a clinical trial are expected to be available during the first half of 2024 and, provided satisfactory results are obtained and subject to financing and regulatory and recruitment preparations. The Company plans to initiate a Phase 1b clinical study, aiming to recruit up to 24 psoriasis patients. This study is expected to be completed before the end of 2024. The Board remains optimistic about Sareum's pipeline of kinase inhibitors.

Star Energy Group 8.05p £10.3m (STAR.L)
The Company focusing on oil and gas extraction but now transitioning to develop and build a geothermal business announces a trading update. The Company remains on track to deliver its full year production target, expected to be c.2,090 boepd. Uptime across the portfolio has remained strong with good results from workovers at Singleton and a rolling programme of well optimisation and stimulation that has yielded additional production equal to c. 50 boepd over this year. The Company holds cash balances as at 30 November 2023 of £2.9m with net debt of £2.6m.

Sutton Harbour Group 14.5p £18.8m (SUH.L)
The marine and waterfront regeneration Company, announces its unaudited interim results for the six-month period to 30 September 2023. Gross profit £1.620m (6 months to 30 September 2022: gross profit £1.415m), however the Company announced a loss before taxation of £0.119m (6 months to 30 September 2022: profit before tax £0.223m). Gross assets marginally increased to £98.859m (31 March 2023: £96.049m) and net debt to £30.468m (31 March 2023: £29.259m). The Company has announced completion of their Harbour Arch Quay and sale of all 14 apartments completed by early November 2023 and has introduced a debt reduction plan to reduce interest burden in 2024.

Zanaga Iron Ore Company 7.74p £46.9m (ZIOC.L)
An iron ore exploration and development company, with the Company's flagship asset being its 100% owned Zanaga Iron Ore Project located in the Republic of Congo announces the appointment of Martin Knauth as Chief Executive Officer with immediate effect. Mr Knauth is a senior mining executive with extensive experience in the industry spanning more than 30 years in a wide range of cultures, countries and commodities.

14 December 2023
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram